Management of Decompensated Chronic Liver Disease (DCLD) with Portal Hypertension, Ascites, and Hepatic Encephalopathy

1. General/Initial Approach

• Admit and assess severity: Child-Turcotte-Pugh and MELD score, look for a precipitating event (infection, GI bleed, drug/alcohol, dehydration, constipation, electrolyte disturbance).
• Screen for infection in every decompensated patient (ascitic fluid analysis, urine, blood, chest X-ray) - infection is the most common precipitant of both ascites decompensation and HE.
• Avoid nephrotoxins and hepatotoxins: NSAIDs, aminoglycosides, and unnecessary sedatives (especially benzodiazepines) are contraindicated.
• Nutrition: adequate calorie (~35 kcal/kg/day) and protein intake (1.2-1.5 g/kg/day); protein should NOT be restricted even in HE, as this worsens muscle wasting and sarcopenia (Sleisenger and Fordtran's Gastrointestinal and Liver Disease).
• Vaccinate (Hepatitis A/B, pneumococcal, influenza) and refer early for transplant evaluation once decompensation occurs.

2. Portal Hypertension / Variceal Bleeding Prophylaxis

• All patients with cirrhosis should be screened by endoscopy for esophageal/gastric varices.
• Primary prophylaxis (varices present, no prior bleed):
  • Non-selective beta-blockers (propranolol, nadolol, or carvedilol) titrated to reduce resting heart rate to 55-60/min or the maximum tolerated dose, or
  • Endoscopic variceal ligation (EVL) for medium/large varices, especially if beta-blockers are contraindicated/not tolerated.
• Acute variceal bleed: resuscitate (restrictive transfusion strategy, target Hb ~7-8 g/dL), start IV vasoactive drugs (octreotide, terlipressin, or somatostatin) as soon as bleeding is suspected, give prophylactic antibiotics (e.g., ceftriaxone) for all cirrhotics with GI bleed, and perform EVL/endoscopic band ligation within 12 hours. TIPS (transjugular intrahepatic portosystemic shunt) is used for refractory or recurrent bleeding.
• Secondary prophylaxis (after a bleed): combination of non-selective beta-blocker + EVL is more effective than either alone.

3. Ascites Management

• Grade 1 (mild, detectable only on imaging): no specific treatment needed.
• Grade 2 (moderate):
  • Sodium restriction: 80-120 mEq/day (~4.6-6.9 g salt/day, "no added salt" diet). Do not restrict more severely - it is poorly tolerated and worsens nutrition.
  • Fluid restriction only if there is dilutional hyponatremia (Na <125 mEq/L).
  • Diuretics: spironolactone (first line, since hyperaldosteronism drives sodium retention) starting at 100 mg/day, combined with furosemide starting at 40 mg/day (typical ratio 100:40), titrated upward every 3-7 days (spironolactone dose changes need at least 72 hours to take effect). Bed rest is not required.
  • Goal: weight loss of 0.5 kg/day (no peripheral edema) or up to 1 kg/day (with edema).
• Grade 3 (tense ascites):
  • Large-volume therapeutic paracentesis as first-line therapy, with IV albumin (6-8 g per liter of ascites removed if >5 L are tapped) to prevent post-paracentesis circulatory dysfunction, followed by diuretics for maintenance.
• Refractory ascites (unresponsive to or intolerant of maximal diuretics):
  • Serial large-volume paracentesis + albumin, or
  • TIPS in appropriate candidates (improves ascites control but carries HE risk), or
  • Transplant evaluation.
• Spontaneous Bacterial Peritonitis (SBP) - must always be excluded/treated in decompensated ascites:
  • Diagnostic paracentesis: ascitic fluid absolute neutrophil count ≥250 cells/mm³ confirms SBP.
  • Treatment: empiric third-generation cephalosporin (e.g., IV cefotaxime or ceftriaxone) plus IV albumin (1.5 g/kg on day 1, 1 g/kg on day 3) if renal impairment or bilirubin >4 mg/dL.
  • Secondary prophylaxis after an SBP episode: long-term norfloxacin or trimethoprim-sulfamethoxazole.
  • Primary prophylaxis in high-risk patients (low ascitic protein <1.5 g/dL with renal/liver failure, or prior GI bleed) with quinolones.

4. Hepatic Encephalopathy (HE) Management

• Identify and correct the precipitant - this is the single most important step. Common triggers: infection/SBP, GI bleeding, constipation, dehydration/diuretic overuse, electrolyte disturbance (hypokalemia, hyponatremia), sedatives, and dietary indiscretion (excess protein in a poorly compensated patient).
• Lactulose (first-line): titrate to 2-3 soft bowel movements/day; works by acidifying colonic contents and trapping ammonia as ammonium, and by cathartic effect that clears nitrogenous waste.
• Rifaximin: added for recurrent/breakthrough HE despite lactulose, or for maintenance of remission; reduces ammoniagenic gut flora with minimal systemic absorption.
• L-ornithine L-aspartate (LOLA): adjunct that promotes ammonia detoxification via the urea cycle/glutamine synthesis; increasingly used, particularly in minimal HE.
• Protein intake: maintain normal-to-high protein intake (avoid restriction); vegetable/dairy protein and branched-chain amino acid (BCAA) supplementation may be better tolerated than animal protein in some patients.
• Avoid sedatives/benzodiazepines; correct hypokalemia and volume depletion carefully (aggressive diuresis can precipitate HE).
• Grading uses the West Haven criteria to stage severity and guide airway/ICU-level care in grade III-IV (stupor/coma).
• Refractory or recurrent overt HE is an indication to reconsider TIPS patency/diameter (if TIPS is present) and to expedite transplant evaluation.

Evidence Update Note

Summary Table

Octreotide Indications in Decompensated Chronic Liver Disease (DCLD)

1. Acute Variceal Bleeding (esophageal/gastric varices)

• Primary indication. Given as an IV bolus followed by continuous infusion as soon as variceal bleeding is suspected, alongside resuscitation, antibiotic prophylaxis, and urgent endoscopy with band ligation/sclerotherapy.
• Mechanism: reduces splanchnic and portal blood flow, lowering portal pressure and variceal wall tension, which helps control bleeding and improves the success of endoscopic hemostasis.
• Typically continued for 2-5 days post-bleed to prevent early rebleeding (Sleisenger and Fordtran's Gastrointestinal and Liver Disease, referencing early vasoactive drug administration in variceal bleeding; also noted in SCHWARTZ'S PRINCIPLES OF SURGERY).
• Used interchangeably with terlipressin or somatostatin depending on availability - terlipressin/somatostatin have similar efficacy to octreotide in this setting.

2. Hepatorenal Syndrome (Type 1 HRS-AKI)

• Second major indication. Octreotide is combined with oral midodrine (an alpha-agonist) and IV albumin to reverse type 1 HRS by counteracting splanchnic vasodilation and improving effective renal perfusion pressure (Current Surgical Therapy 14e, "Vasoconstrictors and Albumin": "Parenteral octreotide has been effective with oral midodrine and albumin in reversing type-1 hepatorenal syndrome").
• This octreotide + midodrine + albumin regimen is the historical standard in the US, particularly where terlipressin was unavailable.
• Important evidence caveat: a recent meta-analysis of RCTs (PMID: 40207491, 2025) found terlipressin + albumin is more effective than octreotide-based regimens for reversing HRS, and terlipressin is now the preferred first-line vasoconstrictor internationally (and FDA-approved in the US since 2022) where available. Octreotide/midodrine remains a reasonable alternative when terlipressin is contraindicated (e.g., significant cardiovascular/ischemic disease) or not accessible.

Not a primary indication in DCLD

• Octreotide is not standard therapy for uncomplicated ascites, hepatic hydrothorax, or hepatic encephalopathy - its portal-pressure-lowering effect is specific to the bleeding/HRS settings above.

Summary